Introduction The use of gender-affirming oestrogen therapy (GAOT) is an integral part of the
gender-affirming transition process for transgender women (assigned male at birth who …

Gender-diverse people likely suffer from higher rates of cardiovascular disease than
cisgender people. Studies on the effects of gender-affirming hormone therapy (GAHT) on …

BACKGROUND For transgender individuals taking hormone therapy (HT), data on
laboratory values are limited, and the effects on laboratory values cannot be easily …

Background There is a paucity of data on the cardiovascular (CV) health of transgender
patients receiving gender-affirming endocrine therapy (GAHT). As prior studies have been …

Aims This study aimed to investigate the association of testosterone replacement therapy
(TTh) with risk of cardiovascular disease (CVD), and CVD-specific outcomes, in cisgender …

Gender affirming hormonal treatment (GAHT) in transgender men consists of testosterone
treatment in different formulations. The main goal of testosterone treatment is to achieve …

BACKGROUND Transgender individuals receiving masculinising or feminising gender-
affirming hormone therapy with testosterone or estradiol respectively, are at increased risk of …

ABSTRACT Study Objective Amenorrhea is a goal of many transgender and gender diverse
adolescent and young adult (TGD AYA) patients on testosterone gender-affirming hormone …

We have treated transgender patients for many years. Our experiences have shaped how
we practice. As a medical student, Saskia Middeldorp had a patient explain what it meant to …

Objective To describe the changes in serum creatinine (Cr) levels after the initiation of
gender-affirming hormone therapy (GAHT) in transgender individuals to better understand …